LC and LC-MS/MS Studies for the Separation and Identification of Impurities and Degradation Products of Betaxolol.
Anis ChmanguiMehdi SaftaMohamed Ridha DrissSoufiane TouilSondes BouabdallahPublished in: Journal of chromatographic science (2024)
Betaxolol (Bx) is a selective β1 receptor blocker used in the treatment of hypertension and glaucoma. The aim of the present work was to demonstrate an approach involving use of liquid chromatography (LC) and liquid chromatography-electrospray ionization mass spectrometry (LC-ESI/MS) for the simultaneous separation, identification and characterization of impurities and of degradation products of betaxolol without their isolation from the reaction mixtures. At optimum condition, and according to ICH guidelines, the limit of detection (LOD) and limit of quantification (LOQ) for Bx are found to be 5.46 and 16.54 μg mL-1, respectively. However, the LOD and LOQ for the major degradation product P6 were 2.15 and 6.53 μg mL-1. Betaxolol was subjected to hydrolytic (acidic and basic) and oxidative, stress conditions according to International Conference on Harmonization (ICH) guideline Q1A (R2), and as results, the drug was found to be labile in acidic, basic and oxidative stress conditions. Based on LC-ESI/MS analysis, the found results revealed that Bx decomposes in acidic, basic and oxidizing environments. All degradation products were identified with the help of their fragmentation pattern and the masses obtained upon the MS analysis.
Keyphrases
- liquid chromatography
- mass spectrometry
- high resolution mass spectrometry
- simultaneous determination
- tandem mass spectrometry
- oxidative stress
- ms ms
- high performance liquid chromatography
- gas chromatography
- ionic liquid
- capillary electrophoresis
- solid phase extraction
- high resolution
- blood pressure
- dna damage
- multiple sclerosis
- computed tomography
- diabetic rats
- angiotensin ii
- optical coherence tomography
- heat shock
- endoplasmic reticulum stress
- electronic health record
- drug induced
- combination therapy
- quantum dots
- binding protein
- real time pcr